Novamab
Shanghai
About Novamab
Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platform and a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $53.9M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2024)
- Website: novamab.com
Industries & Categories
Biotechnology, Pharmaceutical, Product Research, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/novamab-158010 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.